Botox® cost, Singapore (SG)
Botox® cost, Singapore (SG) @singaporebotox_com: Botox® Cosmetic, Dysport®, BTX-A, botulinum toxin type A injection, wrinkle removal treatment clinic, Singapore. Cost/price for treating glabella frown lines, crow's feet, and horizontal forehead lines. Definitions, references, and latest news.
Botox® price. Average Botox® cost.
|Area||IU/spot||Spots||Total IU||Price @ SG$15/IU|
|Horizontal forehead lines||2||8||16||SG$240|
|Glabellar frown lines||4||5||20||SG$300|
Jaw slimming / face slimming / Botox® jaw reduction / Botox® jaw slimming / Botox® face slimming price.
|Area||IU/spot||Spots||Total IU||Price @ SG$15/IU|
|Jaw reduction||8 to 12||6||56||SG$840|
Botox® treatment is with the original Allergan Botox® Cosmetic
- The units differ for different brands.
- Price quoted is for average ladies face, with average musculature.
- Muscular men might require up to twice as much.
- Minimum charge is for 10 units.
Botox® is one of the trade names for botulinum toxin, which is a protein produced by the bacterium clostridium botulinum.
Aesthetic services available:
| Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic: |
| SHIM CLINIC|
168 Bedok South Avenue 3 #01-473
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Botox® cost, Singapore (SG)
| Opening Hours |
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.
Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia
Wed, 19 Nov 2014 00:00:00 +0100 | Parkinsonism and Related Disorders
The development of secondary non-response (SNR) to botulinum neurotoxin type-A (BoNT-A) is considered a key issue in the management of cervical dystonia (CD). This case-controlled study was performed to systematically identify factors influencing SNR during BoNT-A therapy. (Source: Parkinsonism and Related Disorders)
Understanding and treating vaginismus: a multimodal approach
Tue, 18 Nov 2014 13:13:21 +0100 | International Urogynecology Journal
Snapshot: Botox maker’s $66B deal + Ford debuts 500-horsepower Mustang
Tue, 18 Nov 2014 13:12:00 +0100 | bizjournals.com Health Care:Pharmaceuticals headlines
Actavis to Buy Allergan for $66 Billion
Tue, 18 Nov 2014 02:18:49 +0100 | WSJ.com: Health
Actavis agreed to pay $66 billion in cash and stock for Allergan in a deal that appears to have thwarted a hostile takeover of the Botox maker by Valeant and Bill Ackman. (Source: WSJ.com: Health)
Actavis signs agreement to buy Botox-maker Allergan for $66bn
Tue, 18 Nov 2014 00:00:00 +0100 | Pharmaceutical Technology
Ireland-based pharmaceutical company Actavis has signed an agreement to acquire US-based Botox-maker Allergan for $66bn or $219 per share. (Source: Pharmaceutical Technology)
Allergan Sides With More Aggressive Dealmaker By Picking Actavis Over Valeant
Mon, 17 Nov 2014 22:16:00 +0100 | Forbes.com Healthcare News
Botox-maker Allergan is cutting a sweeter deal with an even more acquisitive and hard-charging generic drug maker in Actavis (Source: Forbes.com Healthcare News)
Actavis Nears Deal to Acquire Allergan
Mon, 17 Nov 2014 15:42:01 +0100 | WSJ.com: Health
Actavis is nearing a deal to acquire Allergan in a tie-up that would likely be the year’s largest and could help shield the Botox maker from hostile suitor Valeant. (Source: WSJ.com: Health)
Allergan Agrees To $219 A Share Actavis Takeover Over Bill Ackman-Backed Valeant Deal
Mon, 17 Nov 2014 15:40:00 +0100 | Forbes.com Healthcare News
Botox-maker Allergan has agreed to be sold to generic pharmaceutical manufacturer Actavis for $219 a share in cash and stock. (Source: Forbes.com Healthcare News)
Clinical resistance to three types of botulinum toxin type A in aesthetic medicine
Mon, 17 Nov 2014 00:00:00 +0100 | Journal of Cosmetic Dermatology
Blockade of spinal glutamate recycling produces paradoxical antinociception in rats with orofacial inflammatory pain
Sat, 15 Nov 2014 00:00:00 +0100 | Progress in Neuro Psychopharmacology and Biological Psychiatry
Publication date: 3 March 2015 Source:Progress in Neuro-Psychopharmacology and Biological Psychiatry, Volume 57 Author(s): Kui Y. Yang , Jun H. Mun , Ki D. Park , Min J. Kim , Jin S. Ju , Seong T. Kim , Yong C. Bae , Dong K. Ahn In our current study, we investigated the role of spinal glutamate recycling in the development of orofacial inflammatory pain. DL-threo-β-benzyloxyaspartate (TBOA) or methionine sulfoximine (MSO) was administered intracisternally to block spinal glutamate transporter and glutamine synthetase activity in astroglia. Intracisternal administration of high dose TBOA (10μg) produced thermal hyperalgesia in naïve rats but significantly attenuated the thermal hyperalgesia in rats that had been pretreated with interleukin (IL)-1β or Complete Freund's Adjuvant (CFA). ...